Company Overview

Ortin Global Ltd, formerly known as Ortin Laboratories Limited, was incorporated in October 1986. The company is primarily engaged in the manufacturing and trading of Pharmaceuticals, Drugs, and Intermediates. It specializes in pharmaceutical manufacturing within the healthcare sector, focusing on providing quality medicines and drugs. Their product range includes anti-arthritic drugs, antibiotics, chemotherapy drugs, analgesics, cardiac and cardiovascular drugs, and various other medicinal formulations. Over time, Ortin Global has expanded its operations internationally.

Business Operations and Expansion

Ortin Global has shown growth since its establishment. In 2003-04, they began marketing products across various states and were listed on BSE Indonext in 2006-07. The company has successfully exported its products to African, Asian, and Middle Eastern countries and obtained the National Drug Authority Uganda certification in 2009-10.

In 2010-11, Ortin Global acquired Vineet Laboratories Pvt Ltd and secured 6.18 acres of land from APIIC for constructing a USFDA and European Standard Bulk Drug manufacturing facility. This strategic move underscores their commitment to meeting global quality standards and enhancing manufacturing capabilities.

The company's product portfolio is extensive, including:

- Active Pharmaceutical Ingredient (API) Intermediates: Anti-retroviral, anti-diabetics, analgesics and antipyretics, anti-biotics, anti-fungal, anti-acids and anti-ulcerants, and anti-malarials.

- Fine Chemicals: Including grignard and alkali metal products.

- Services: Process development, process and product characterization, analytical research and development, assay development, R&D for new formulation brands, and diagnostic services (rapid flow kits, assays, reagents).

- Contracts: Undertakes long-term contracts for manufacturing intermediates and developing new APIs.

- Merchant Exports: Operates as a merchant exporter of pharmaceutical finished formulations.

- Real Estate: Engages in real estate activities.

Stock Market Information

Ortin Global Ltd (ORTINGLOBE) operates in the Health Care sector, specifically the Pharmaceuticals sub-sector. The company is listed on both major Indian stock exchanges:

- BSE Code: 539287

- NSE Symbol: ORTINGLOBE

- ISIN: INE749B01020

The stock has experienced significant volatility.

- 52-Week High: ₹24.82

- 52-Week Low: ₹9.64

Over the last 5 years, revenue has grown at a yearly rate of -57.68%, compared to the industry average of 9.04%, indicating challenges in maintaining growth momentum.

Market Capitalization and Valuation Metrics

- Market Capitalization: ₹8.31 Cr (as of May 9, 2025)

- This places Ortin Global Ltd in the small-cap segment of the Indian equity market.

Key valuation metrics provide insights into the market's perception of the company's assets and profitability:

- P/E Ratio: -1.03

- A negative P/E ratio suggests the company has been reporting losses.

- P/B Ratio: 2.95

- The stock is trading at 2.95 times its book value.

Financial Performance

The company's recent financial performance has been challenging, showing losses and declining sales across multiple quarters.

- Q3 FY2024-25 (Quarter ended December 2024):

- Net Loss: ₹0.11 crore (vs. Net Loss of ₹2.79 crore in Q3 FY2023-24)

- Sales: ₹0.03 crore (declined 78.57% vs. ₹0.14 crore in Q3 FY2023-24)

- Q2 FY2024-25 (Quarter ended September 2024):

- Net Loss: ₹0.47 crore (vs. Net Loss of ₹1.12 crore in Q2 FY2023-24)

- Sales: ₹0.05 crore (declined 80.77% vs. ₹0.26 crore in Q2 FY2023-24)

- Q1 FY2024-25 (Quarter ended June 2024):

- Net Loss: ₹0.10 crore (vs. Net Profit of ₹0.02 crore in Q1 FY2023-24)

- Sales: ₹0.21 crore (declined 86.62% vs. ₹1.57 crore in Q1 FY2023-24)

Overall, recent data indicates:

- Revenue: ₹0.59 Cr

- Net Loss: ₹4.82 Cr

The company also faces financial leverage concerns, evidenced by a low interest coverage ratio.

Key Financial Metrics

- Market Cap: ₹8.31 Cr (as of May 9, 2025)

- P/E Ratio: -1.03

- P/B Ratio: 2.95

- Revenue (Recent Period): ₹0.59 Cr

- Net Loss (Recent Period): ₹4.82 Cr

- 52-Week High: ₹24.82

- 52-Week Low: ₹9.64

- Promoter Holding: 1.23% (as of Mar 2025)

Shareholding Pattern

The shareholding pattern as of March 2025 is as follows:

- Promoters: 1.23%

- Institutions: 6.53%

- Public: 92.24%

The promoter holding represents a relatively low stake in the company, with the majority of shares held by public investors.

Recent Corporate Actions and Compliance

Ortin Global Ltd has been maintaining regular compliance with regulatory requirements. The company confirms non-applicability of SEBI Large Corporate criteria as of March 31, 2025. Regular board meetings are conducted to discuss business operations and strategic decisions.

Ortin Global Ltd operates in a competitive pharmaceutical sector where regulatory compliance, product quality, and operational efficiency are critical for success. While the company has established manufacturing capabilities and an international presence, recent financial performance indicates operational challenges that investors should carefully consider when evaluating investment opportunities in this stock.